Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease

This study has been terminated.
(Termination of the clinical development program by the Sponsor)
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01059682
First received: January 29, 2010
Last updated: August 8, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2011
  Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 26, 2016
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):